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OBJECTIVES: To demonstrate a simplified approach to cost-effectiveness analysis
of new diagnostic tests based on minimal information and without developing a
full decision-analytic modeling framework, which is often complex, time consum-
ing and potentially inefficient. METHODS: Using a simplified decision-analytic ap-
proach to the complete pathway of care from diagnosis to subsequent treatment,
cost-effectiveness of the new diagnostic test is expressed as a mathematical func-
tion of diagnostic accuracy, cost, burden, and the cost-effectiveness of treatment.
This function only includes parameters available during early test development
phases and does not require any simulation. Parameter uncertainty is accounted
for by applying probabilistic sensitivity analysis. In a clinical example, the cost-
effectiveness of magnetic resonance angiography (MRA) compared with digital
subtraction angiography (DSA) for the detection of new intracranial aneurysms is
assessed in patients with previous subarachnoid hemorrhage. RESULTS: The sim-
plified approach produced cost-effectiveness results for MRA compared with DSA
in line with our previous and similar, but much more comprehensive assessment.
The comprehensive assessment resulted in a net monetary benefit (NMB) of $1,910
(95%CI 1,809 to 5,565) and probabilities of effectiveness and cost-effectiveness of
98% and 87%, respectively (Willingness-to-pay threshold $50,000 per QALY). Our
simplified approach returned a NMB of $1,779 (95%CI 1,170 to 2,477) with corre-
sponding probabilities of effectiveness and cost-effectiveness of 100% and 98%,
respectively. Hence, the simplified approach would already have provided a clear
indication of the potential benefits of replacing DSA with MRA. CONCLUSIONS:
Given the abundance of new diagnostic tests an approximation of the cost-effec-
tiveness of new tests at minimal costs is highly valuable. Our low-cost mathemat-
ical satisficing approach supports improved use of health care resources by indi-
cating 1) which tests are promising; 2) which tests are not promising; and 3) which
tests require more rigorous economic evaluations to obtain improved estimates of
cost-effectiveness but at a higher use of health care resources.
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OBJECTIVES: To present an effective and elegant model approach to deal with
specific characteristics of complex modeling. METHODS: A discrete event simula-
tion (DES) model with multiple complications and multiple outcomes that each can
occur simultaneously was developed. In this DES model parameters, attributes and
distributions were estimated based on patient population (patient-level DES
model). Next to this, the DES model was constructed in such a way that it is par-
ticularly capable to deal with: different disease states, multiple complications, and
multiple long-term outcomes. Our model was designed for comparing two radia-
tion treatments (photon vs. proton) for head and neck cancer. In this model the
following elements were included: different disease states (local recurrency, dis-
tance metastasis, and combinations), simultaneous complications (xerostomia,
sticky saliva, dysphagia, and thyroid dysfunction), and multiple long-term out-
comes (overall survival, quality of life, costs). Estimates were based on the patient
population (n1013) treated with radiation therapy for head and neck tumor and
combined with literature based estimates. RESULTS: The following discrete events
were scheduled by a so-called statechart (system of graphical specification): pri-
mary tumor, mortality, time-to-event, and disease states. These events are sched-
uled with transitions following distributions that depend on tumor and other pa-
tient characteristics. In addition, the model contains a module for the primary
tumor prognosis, and separate, parallel modules/events for each important com-
plication. Costs and values of health for the different states/complications and
combined to cost-effectiveness are included. CONCLUSIONS: This elaborated DES
model allows multiple complications and outcomes to be modeled in parallel and
is suited to estimate the long-term effects. The global structure of our model can be
interesting for modeling other diseases that are associated with complex treat-
ment regimes and multiple complications. In addition, side effects in parallel to
main effects can be modeled and multiple outcomes of new pharmaceuticals com-
pared to current medication.
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OBJECTIVES: To identify the possible problems and trends regarding health eco-
nomic modelling in Hungarian Health Technology Assessment. We were especially
interested in the general quality of health economic models. METHODS: We ana-
lyzed the submissions which were based on a health economic model, which were
assessed by the Hungarian HTA Office since 2004. We created a database in which
we summed up our findings: the type of the model, the quality and robustness of
the model, the type of disease which was modelled. We sorted the models by these
criteria and searched for correlations. We attempted to set some indicators regard-
ing the quality of models. We also analysed some methodological and procedural
problems from multiple aspects related to modelling in Hungary. RESULTS: Our
findings show that the use of health economic models is increasing and that most
of the models are decision tree and Markov types. The submitted Markov models
are from the subtype of Markov chain models with only a few exceptions. Primarily
simulation models are only used in a small share of submissions (11%), especially
in the cases of chronic diseases. Trends show that the proportion of Markov models
which have probabilistic sensitivity analyses are also increasing (from 0% to nearly
30%). The submitted models became more detailed and they show a distinct im-
provement in methodology during the past 8 years. These factors indicate the
general improvement of the quality of Hungarian health economic modelling.
CONCLUSIONS: Although it is not compulsory in Hungary, more and more manu-
facturers present or submit health economic models to the Department of Health
Technology Assessment. Based on our findings, several factors indicate that the
submitted models are getting more detailed, and better of quality.
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OBJECTIVES: To compare the computation speed when running a microsimulation
model and probabilistic sensitivity analysis (PSA) on four widely-available pro-
gramming platforms: Excel, Visual Basic for Applications (VBA), R, and Java.
METHODS: A simple microsimulation model predicting the number of handouts
collected by 2500 ISPOR attendees during a congress was created to test efficiency
measured by model running speed. Speed was based on the system time and
included only the portion of code used to run the model, excluding any code for
parameter input or output. Calculations were performed on a computer running
Windows 7, dual core 2.6 GHz processor, with 4 GB RAM. All platforms except Excel
were cross-validated by using a list of pseudo-random numbers as model inputs to
ensure consistency of model outputs. PSA was conducted by sampling random
probabilities from beta distributions and replicating the model 1000 times. Ten
simulations of each base-case and PSA model type were run to assess variability in
platform efficiency. RESULTS: The speed of Excel could not be timed in the base-
case microsimulation since results were calculated instantly. VBA was slower than
R with means of 0.09 seconds and 0.02 seconds, respectively. Java generated a
system time of zero, indicating the program required 0.001s. The Excel PSA sim-
ulations required the most time with 33.4s, followed by VBA (29.4s). R required
19.0s and Java required the least amount of time (4.0s). CPU usage for PSA simula-
tions was highest with Excel (80%) and similar for all other platforms (25%).
CONCLUSIONS:With the obvious caveats that program speed is a function of com-
puting power and coding efficiency, the results of this analysis demonstrate Java
was consistently faster than Excel, VBA and R, which are commonly used for phar-
macoeconomic models. With increasing model complexity and running times, ex-
ploration of alternate implementations for their execution is recommended.
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The current recommendations for the conservative management of overactive
bladder symptoms and detrusor overactivity, given by NICE 2012, are pelvic floor
muscle training, bladder training, sacral nerve stimulation, mid-urethral tape and
antimuscarinic drugs- oxybutynin, darifenacin, solifenacin, tolterodine, and trop-
sium. More recently, emerging evidence suggests that Botulinum toxin type A is
also an effective intervention for overactive bladder and idiopathic detrusor over-
activity. Although a number of meta-analyses have been published reporting pair-
wise comparisons of the various interventions, to date no network meta-analysis
has been undertaken comparing all interventions simultaneously.OBJECTIVES: To
evaluate the clinical effectiveness of drug therapy, neuromodulation, botulinum
toxin, and behaviour therapy, in the prevention of overactive bladder symptoms
and detrusor overactivity.METHODS:Mixed treatment network meta-analyses for
the individual, and classes (i.e. behaviour, drugs etc.), of interventions using Win-
BUGS. The correlations between the interventions within a class were addressed by
conducting a mixed treatment network meta-analysis using a hierarchical model
structure. RESULTS: Evaluation of the class of interventions, i.e. ‘lumping’ individ-
ual interventions with classes, demonstrates an increased precision in the out-
come; however, categorising the interventions decreases the interpretability of the
results. At the individual intervention level, the sparseness of the data decreases
the precision of the estimates, but enables comparisons to be made between indi-
vidual interventions. The hierarchical model, allows both increased precision, due
to the utilisation of all of the available data, whilst still allowing comparisons to be
made between individual interventions both within and between classes.
CONCLUSIONS: Use of a hierarchical model increases the interpretability of the
mixed treatment network meta-analysis whilst maximising the precision in terms
of outcome. However, defining the hierarchical structure can prove difficult in
some instances, with potential comparators residing at different levels in the hi-
erarchy.
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OBJECTIVES: Cost-effectiveness studies of health technologies where data are ex-
trapolated from short term clinical trials to estimate results over appropriate de-
cision making time horizons typically assume that the decision context remains
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constant. More recently, it has been argued that a ‘life cycle’ approach should be
routinely applied to technology assessments, including incorporating anticipated
changes in price. Since the results from these different approaches can have im-
portant implications for reimbursement and conditional coverage decisions, it is
critical that rationale and methods for incorporating future changes are more
clearly defined. The aims of this research are to: i) establish the key principles and
assessments related to incorporating future changes when extrapolating cost-ef-
fectiveness results; ii) consider how additional information and analyses could be
used to more appropriately inform a range of policy decisions. METHODS: We
reviewed existing literature investigating future changes in the decision context
due to price, technological developments and the information available to decision
makers to examine their relevance and implications for cost-effectiveness meth-
ods and approaches to extrapolation. A case study evaluating the cost-effective-
ness of biologics for the treatment of psoriatic arthritis is used to demonstrate the
impact of modelling a changing context on both the magnitude and the uncertainty
around cost-effectiveness results. RESULTS: Our results show that incorporating
anticipated changes in the decision context, particularly where decisions made are
irreversible, can have a dramatic effect on the extrapolation of cost-effectiveness
results both in terms of determining the optimal treatment decision and in terms of
characterising the level and consequences of uncertainty around these results.
CONCLUSIONS:A changing decision context can have a significant impact on cost-
effectiveness results and the conclusions drawn from these results. This changing
decision context so far as it can be anticipated should therefore be modelled to
allow us to make the best possible decisions incorporating all available informa-
tion.
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OBJECTIVES: There has been substantial debate on the need for differential dis-
counting for monetary and health gains in economic evaluations. A way to identify
the need for such discounting strategies, is through eliciting the societal time pref-
erences for monetary and health outcomes. In this article we investigate the time
preference for money and health gains through a pilot survey on Dutch university
students. METHODS: Fifty university students completed three questionnaires on
their intertemporal choices for quality of life, life years and money. We quantified
the participants’ time preferences, and fitted a variety of functional forms between
the time of delay and their discount rate. We followed a non-linear mixed regres-
sion modeling approach with heteroscedasticity correction. RESULTS: Non-linear
regression estimates indicated a power function as the most appropriate func-
tional form for the discount rate. High within-individual correlations were esti-
mated through the mixed-effect approach. Finally, a negative relation between the
time of delay and the variance of the discount rate was observed for all models.
CONCLUSIONS: The evidence collected in this study pinpoint to differential time
preference of society, with a stronger preference for the near rather than the dis-
tant future. Additionally the advantages of a non-linear mixed model approach
were illustrated in such data with high within-individual correlation. However,
inference that can be utilized for decision making in the Netherlands requires a
larger, more representative sample of the Dutch population. For that reason, a large
nation-wide survey has been recently set forth.
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OBJECTIVES: As part of the IFEDH (Innovative Framework for Evidence based De-
cision making in Healthcare) research project (FFG grant number 827347) a cost
effectiveness analysis of systematic population based screening for abdominal
aortic aneurysm (AAA) in Austria has to be performed. The modeling method se-
lection process is conducted in detail, taking into account the possible influence of
chronic disease, smoking and gender. METHODS: In parallel three different strat-
egies are performed. The first one is a non systematic literature research on AAA
screening modeling concepts in Europe. The second deals with modeling concepts
available in the research project, mainly Markov models, agent based modeling
techniques and System Dynamics. The third part deals with a data overview from
Austrian Health service providers, identifying risk factors to be taken into account
as well as literature research on this topic. Based on the described tasks an inter-
disciplinary group from the field of HTA, data quality assessment, mathematical
modeling and statistics choose the best suited modeling concept. RESULTS: Based
on the identified literature on AAA screening modeling, the analyzed situation
regarding smoking behavior and chronic diseases as well as technical classification
of the benefits of the different methods an agent based simulation model has been
chosen. Detailed modeling concepts are developed and the implementation phase
is started. Due to the bottom-up approach the original data can be implemented
without transformations, leading to higher reliability. CONCLUSIONS: The devel-
opment of modern modeling methods in the IFEDH project in advance as well as
setting up an interdisciplinary team leads to higher performance regarding overall
project working time, quality in the decision process and realization of an AAA
screening model for Austria. Agent based modeling techniques are identified as
most flexible and well suited in the Austrian context.
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Kaplan-Meier (KM) survival analysis forms a cornerstone of the oncology mod-
eller’s toolkit. KM time-to-event data is often utilised by decision analysts to inform
a range of oncology model inputs. These may include the probability of a patient
dying, progressing or ceasing treatment over the course of a model’s time horizon
(typically key determinants of the incremental QALY and cost associated with an
intervention). As KM data is often incomplete, extrapolation beyond the period
observed is generally required. Extrapolation of KM data in several recent NICE
technology appraisals has moved away from the mechanical application of statis-
tical functions on the basis of ‘best-statistical fit’ as determined by Akaike and
Bayesian Information Criterion (a method used by manufacturers in a range of
previous NICE appraisals) to the use of extrapolation informed by consideration of
cumulative hazard plots. OBJECTIVES: To demonstrate the use of cumulative haz-
ard plots, their interpretation and their ability to inform resource allocation and
research decisions in health care. METHODS: A series of blinded case studies of
oncology pharmaceutical interventions assessed in NICE’s STA program are pre-
sented. These case studies demonstrate the importance of appropriately consider-
ing cumulative hazard plots when assessing the cost-effectiveness of pharmaceu-
tical technologies in oncology. RESULTS: Appropriate interpretation of cumulative
hazard plots can 1) help inform rational, rather than mechanical, extrapolation of
survival data; 2) can assist an analyst in explaining the discordance between sta-
tistical functions found to be the ‘best-fit’ by traditional test-based approaches and
subsequent poor face validity when compared to observed data; and 3) can be
utilised to generate hypotheses that may be tested in future clinical research (par-
ticularly the assessment of the effectiveness and cost-effectiveness of restricted/
extended durations of treatment). CONCLUSIONS: Measured consideration of cu-
mulative hazard plots from both RCT and observational data is essential to inform
appropriate decision making in oncology.
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OBJECTIVES: To estimate the cost and Quality Adjusted Life Years of tirofiban,
abciximab and eptifibatide plus standard care versus standard care alone in ST-
elevated myocardial infarction and Non ST-elevated (NSTE) Acute Coronary Syn-
drome (ACS) in England and Wales. METHODS: A lifetime state transition model
was constructed to conduct a cost utility analysis comparing low dose (for first 30
minutes, 0.4mg per minute, followed by 0.1 micrograms per kg per minute there-
after) tirofiban, standard dose abciximab (initially 250 micrograms per kg, followed
by 125 nanograms per kg per minute thereafter) or standard dose eptifibatide (ini-
tially 180 micrograms per kg, followed by 2 micrograms per kg per minute) added to
standard care in two populations: primary percutaneous coronary angioplasty in
STEMI and an Early Invasive strategy in medium to high risk NSTE ACS. Relative
Risks of death, bleeding, myocardial infarction and urgent revascularisation came
from a systematic review. Probabilistic sensitivity analysis was performed.
RESULTS: In STEMI, tirofiban plus standard care dominated the other interventions
in both with or without future unrelated illness cost. The Incremental Cost Effec-
tiveness Ratio (ICER) versus standard care only varied from approximately £1150 to
£9,000. In NSTE ACS, eptifibatide plus standard care dominated the other interven-
tions: the CER versus standard care varied from £1100 without to £7700 with unre-
lated illness costs. CONCLUSIONS: The addition of tirofiban to standard care in
STEMI is likely to be cost effective when a low dose bolus was administered fol-
lowed by continuous low dose infusion during primary percutaneous coronary
angioplasty. In the medium to high risk NSTE ASC population, eptifibatide could be
cost effective. However, there is much uncertainty in many parameters in both
target groups, largely due to lack of randomised controlled trial evidence. We rec-
ommend consideration of further research, particularly larger trials.
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OBJECTIVES: Common methods to visualize Markov states over time (e.g., Markov-
cycle trees or state probability graphs) do not scale well to many cycles and have
limitations concerning the perception of proportions. An objective of the IFEDH
research project (FFG grant number 827347) was to overcome these limits by inves-
tigating new visualization methods of Markov models and their results.METHODS:
Inspired by the “Parallel Coordinates”, an interactive technique called Parallel Sets
has been developed for visualizing multidimensional categorical data. The visual-
ization lays out axes in a parallel way where each axis represents one categorical
dimension. Within each axis, boxes represent the categories which are scaled ac-
cording to the respective frequencies. Applied to Markov Models, the categorical
dimensions correspond to the various cycles. Joint probabilities of categories from
adjacent axes are shown as parallelograms connecting the respective categories.
The parallelograms can be interpreted as the number of patients transiting from
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